{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:45:38Z","timestamp":1791049538245,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["AP1144791"],"award-info":[{"award-number":["AP1144791"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Tuition Fee Scholarship from Murdoch University and scholarships","award":["AP1144791"],"award-info":[{"award-number":["AP1144791"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Dysferlin is a large transmembrane protein involved in critical cellular processes including membrane repair and vesicle fusion. Mutations in the dysferlin gene (DYSF) can result in rare forms of muscular dystrophy; Miyoshi myopathy; limb girdle muscular dystrophy type 2B (LGMD2B); and distal myopathy. These conditions are collectively known as dysferlinopathies and are caused by more than 600 mutations that have been identified across the DYSF gene to date. In this review, we discuss the key molecular and clinical features of LGMD2B, the causative gene DYSF, and the associated dysferlin protein structure. We also provide an update on current approaches to LGMD2B diagnosis and advances in drug development, including splice switching antisense oligonucleotides. We give a brief update on clinical trials involving adeno-associated viral gene therapy and the current progress on CRISPR\/Cas9 mediated therapy for LGMD2B, and then conclude by discussing the prospects of antisense oligomer-based intervention to treat selected mutations causing dysferlinopathies.<\/jats:p>","DOI":"10.3390\/ijms25115572","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:26:27Z","timestamp":1716261987000},"page":"5572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities"],"prefix":"10.3390","volume":"25","author":[{"given":"Bal Hari","family":"Poudel","sequence":"first","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA 6150, Australia"},{"name":"Perron Institute for Neurological and Translational Science, The University of Western Australia, Perth, WA 6009, Australia"},{"name":"Central Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu 44618, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-641X","authenticated-orcid":false,"given":"Sue","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA 6150, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve D.","family":"Wilton","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA 6150, Australia"},{"name":"Perron Institute for Neurological and Translational Science, The University of Western Australia, Perth, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-2303","authenticated-orcid":false,"given":"May","family":"Aung-Htut","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA 6150, Australia"},{"name":"Perron Institute for Neurological and Translational Science, The University of Western Australia, Perth, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/1682","article-title":"Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy","volume":"20","author":"Liu","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"50466","DOI":"10.1074\/jbc.M307247200","article-title":"Dysferlin interacts with Annexins A1 and A2 and mediates sarcolemmal wound-healing","volume":"278","author":"Lennon","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/geno.2000.6290","article-title":"The third human FER-1-like protein is highly similar to dysferlin","volume":"68","author":"Britton","year":"2000","journal-title":"Genomics"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bulankina, A.V., and Thoms, S. (2020). Functions of Vertebrate Ferlins. Cells, 9.","DOI":"10.3390\/cells9030534"},{"key":"ref_5","first-page":"2004","article-title":"Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development","volume":"9","author":"Quijano","year":"2020","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1038\/s41598-020-63461-2","article-title":"Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease","volume":"10","author":"Ham","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_7","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E2317","DOI":"10.1002\/humu.22015","article-title":"UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene","volume":"33","author":"Blandin","year":"2012","journal-title":"Hum. Mutat."},{"key":"ref_9","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Mirzaa, G.M., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ceb.2007.07.001","article-title":"Dysferlin and muscle membrane repair","volume":"19","author":"Han","year":"2007","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/mus.20106","article-title":"Developmental and tissue-specific regulation of a novel dysferlin isoform","volume":"30","author":"Salani","year":"2004","journal-title":"Muscle Nerve"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00439-006-0230-1","article-title":"Identification and characterization of a novel human dysferlin transcript: Dysferlin_v1","volume":"120","author":"Pramono","year":"2006","journal-title":"Hum. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1212\/WNL.57.2.271","article-title":"Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy","volume":"57","author":"Aoki","year":"2001","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/hmg\/8.5.855","article-title":"Dysferlin is a plasma membrane protein and is expressed early in human development","volume":"8","author":"Anderson","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gallardo, E., de Luna, N., Diaz-Manera, J., Rojas-Garcia, R., Gonzalez-Quereda, L., Flix, B., de Morree, A., van der Maarel, S., and Illa, I. (2011). Comparison of Dysferlin Expression in Human Skeletal Muscle with That in Monocytes for the Diagnosis of Dysferlin Myopathy. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0029061"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10949","DOI":"10.1038\/s41598-018-29184-1","article-title":"FerA is a Membrane-Associating Four-Helix Bundle Domain in the Ferlin Family of Membrane-Fusion Proteins","volume":"8","author":"Harsini","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bpj.2013.11.4492","article-title":"Quantitation of the calcium and membrane binding properties of the C2 domains of dysferlin","volume":"106","author":"Abdullah","year":"2014","journal-title":"Biophys. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.273.5272.248","article-title":"Bipartite Ca2+-binding motif in C2 domains of synaptotagmin and protein kinase C","volume":"273","author":"Shao","year":"1996","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1021\/bi400432f","article-title":"The C2 Domains of Otoferlin, Dysferlin, and Myoferlin Alter the Packing of Lipid Bilayers","volume":"52","author":"Marty","year":"2013","journal-title":"Biochemistry"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sula, A., Cole, A.R., Yeats, C., Orengo, C., and Keep, N.H. (2014). Crystal structures of the human Dysferlin inner DysF domain. BMC Struct. Biol., 14.","DOI":"10.1186\/1472-6807-14-3"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tcb.2004.03.001","article-title":"Dysferlin and the plasma membrane repair in muscular dystrophy","volume":"14","author":"Bansal","year":"2004","journal-title":"Trends Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1600-0854.2007.00573.x","article-title":"Dysferlin in membrane trafficking and patch repair","volume":"8","author":"Glover","year":"2007","journal-title":"Traffic"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1161\/ATVBAHA.110.208108","article-title":"A new role for the muscle repair protein dysferlin in endothelial cell adhesion and angiogenesis","volume":"30","author":"Sharma","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1523\/JNEUROSCI.3560-12.2013","article-title":"Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair","volume":"33","author":"Lek","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2044-5040-1-10","article-title":"Muscle membrane repair and inflammatory attack in dysferlinopathy","volume":"1","author":"Han","year":"2011","journal-title":"Skelet. Muscle"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20831","DOI":"10.1073\/pnas.1307960110","article-title":"Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane","volume":"110","author":"Kerr","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77998","DOI":"10.3389\/fphys.2014.00089","article-title":"Dysferlin at transverse tubules regulates Ca2+ homeostasis in skeletal muscle","volume":"5","author":"Kerr","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1113\/JP282648","article-title":"The C2 domains of dysferlin: Roles in membrane localization, Ca(2+) signalling and sarcolemmal repair","volume":"600","author":"Muriel","year":"2022","journal-title":"J. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/BCJ20200773","article-title":"Calcium binds and rigidifies the dysferlin C2A domain in a tightly coupled manner","volume":"478","author":"Wang","year":"2021","journal-title":"Biochem. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.nmd.2016.08.008","article-title":"Dysferlin mutations and mitochondrial dysfunction","volume":"26","author":"Vincent","year":"2016","journal-title":"Neuromuscular Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14575","DOI":"10.1074\/jbc.M116.727016","article-title":"Dysferlin Binds SNAREs (Soluble N-Ethylmaleimide-sensitive Factor (NSF) Attachment Protein Receptors) and Stimulates Membrane Fusion in a Calcium-sensitive Manner","volume":"291","author":"Codding","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1242\/jcs.198861","article-title":"Dysferlin mediates membrane tubulation and links T-tubule biogenesis to muscular dystrophy","volume":"130","author":"Hofhuis","year":"2017","journal-title":"J. Cell Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/europace\/euaa093","article-title":"Dysferlin links excitation-contraction coupling to structure and maintenance of the cardiac transverse-axial tubule system","volume":"22","author":"Hofhuis","year":"2020","journal-title":"Europace"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajpath.2013.09.009","article-title":"Dysferlin and myoferlin regulate transverse tubule formation and glycerol sensitivity","volume":"184","author":"Demonbreun","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ajpath.2016.02.005","article-title":"Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption","volume":"186","author":"Demonbreun","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1083\/jcb.201512022","article-title":"An actin-dependent annexin complex mediates plasma membrane repair in muscle","volume":"213","author":"Demonbreun","year":"2016","journal-title":"J. Cell Biol."},{"key":"ref_37","first-page":"F39","article-title":"Unique S100 target protein interactions","volume":"28","author":"Rezvanpour","year":"2009","journal-title":"Gen. Physiol. Biophys."},{"key":"ref_38","first-page":"134","article-title":"Intracellular localization of dysferlin and its association with the dihydropyridine receptor","volume":"24","author":"Ampong","year":"2005","journal-title":"Acta Myol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1212\/01.wnl.0000204358.89303.81","article-title":"Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy","volume":"66","author":"Sinnreich","year":"2006","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ejhg.2011.70","article-title":"Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations","volume":"19","author":"Cacciottolo","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_41","unstructured":"Krahn, M. (2018, September 15). The UMD-DYSF Locus-Specific Database. [Web Page] 2011 06\/26\/2015. Available online: http:\/\/www.umd.be\/DYSF\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/humu.24036","article-title":"The genetic profile of dysferlinopathy in a cohort of 209 cases: Genotype-phenotype relationship and a hotspot on the inner DysF domain","volume":"41","author":"Izumi","year":"2020","journal-title":"Hum. Mutat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E345","DOI":"10.1002\/humu.20910","article-title":"Analysis of the DYSF mutational spectrum in a large cohort of patients","volume":"30","author":"Krahn","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/humu.24284","article-title":"Molecular landscape of DYSF mutations in dysferlinopathy: From a Chinese multicenter analysis to a worldwide perspective","volume":"42","author":"Zhong","year":"2021","journal-title":"Hum. Mutat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4103\/0366-6999.190671","article-title":"Dysferlin Gene Mutation Spectrum in a Large Cohort of Chinese Patients with Dysferlinopathy","volume":"129","author":"Jin","year":"2016","journal-title":"Chinese Med. J.-Peking."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neulet.2017.10.048","article-title":"Novel, de novo dysferlin gene mutations in a patient with Miyoshi myopathy","volume":"664","author":"Hu","year":"2018","journal-title":"Neurosci. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1293\/tox.25.135","article-title":"Dysferlin and animal models for dysferlinopathy","volume":"25","author":"Kobayashi","year":"2012","journal-title":"J. Toxicol. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Rayavarapu, S., Van der Meulen, J.H., Gordish-Dressman, H., Hoffman, E.P., Nagaraju, K., and Knoblach, S.M. (2010). Characterization of dysferlin deficient SJL\/J mice to assess preclinical drug efficacy: Fasudil exacerbates muscle disease phenotype. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012981"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00001756-200103050-00039","article-title":"Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation","volume":"12","author":"Vafiadaki","year":"2001","journal-title":"Neuroreport"},{"key":"ref_50","unstructured":"The Jackson Laboratory (2018, August 11). Mouse Strain Datasheet, Available online: https:\/\/www.jax.org."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtn.2018.08.013","article-title":"Exon Skipping in a Dysf-Missense Mutant Mouse Model","volume":"13","author":"Malcher","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/sctm.18-0280","article-title":"Phenotypic Drug Screening for Dysferlinopathy Using Patient-Derived Induced Pluripotent Stem Cells","volume":"8","author":"Kokubu","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2353\/ajpath.2008.080098","article-title":"Dysferlin deficiency shows compensatory induction of Rab27A\/Slp2a that may contribute to inflammatory onset","volume":"173","author":"Kesari","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2353\/ajpath.2008.070327","article-title":"Dysferlin deficiency enhances monocyte phagocytosis: A model for the inflammatory onset of limb-girdle muscular dystrophy 2B","volume":"172","author":"Nagaraju","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/humu.9355","article-title":"Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies","volume":"26","author":"Nguyen","year":"2005","journal-title":"Hum. Mutat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2990.2002.00417.x","article-title":"Muscle pathology in dysferlin deficiency","volume":"28","author":"Fanin","year":"2002","journal-title":"Neuropath Appl. Neuro"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXG.0000000000000089","article-title":"The Clinical Outcome Study for dysferlinopathy: An international multicenter study","volume":"2","author":"Harris","year":"2016","journal-title":"Neurol. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4103\/aian.AIAN_129_17","article-title":"Detection of Dysferlin Gene Pathogenic Variants in the Indian Population in Patients Predicted to have a Dysferlinopathy Using a Blood-based Monocyte Assay and Clinical Algorithm: A Model for Accurate and Cost-effective Diagnosis","volume":"20","author":"Dastur","year":"2017","journal-title":"Ann. Indian. Acad. Neur"},{"key":"ref_60","first-page":"938","article-title":"Mutational and clinical features of Japanese patients with dysferlinopathy (Miyoshi myopathy and limb girdle muscular dystrophy type 2B)","volume":"45","author":"Takahashi","year":"2005","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/mus.25367","article-title":"Progress and challenges in diagnosis of dysferlinopathy","volume":"54","author":"Fanin","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0960-8966(00)00143-7","article-title":"Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies)","volume":"10","author":"Anderson","year":"2000","journal-title":"Neuromuscul. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jns.2006.07.004","article-title":"Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions","volume":"250","author":"Therrien","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"ref_64","unstructured":"(2024, March 07). Clinicaltrials.gov. rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies. The Proposed Clinical Trial is a Double-Blind, Randomized Controlled Study with Direct Intramuscular Injection of rAAVrh.74.MHCK7.DYSF.DV Gene Vector to the Extensor Digitorum Brevis Muscle (EDB). Two Cohorts of Subjects with Dysferlin Deficiency, Each with Proven Mutations will Undergo Gene Transfer. A Minimum of Three Subjects will be Enrolled into Each Cohort.], Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02710500."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI34316","article-title":"Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice","volume":"118","author":"Allocca","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/hmg\/ddq065","article-title":"Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer","volume":"19","author":"Lostal","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acn3.172","article-title":"AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models","volume":"2","author":"Sondergaard","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/hum.2017.062","article-title":"Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy","volume":"29","author":"Potter","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Grose, W.E., Clark, K.R., Griffin, D., Malik, V., Shontz, K.M., Montgomery, C.L., Lewis, S., Brown, R.H., Janssen, P.M.L., and Mendell, J.R. (2012). Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039233"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/mtm.2015.9","article-title":"A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence","volume":"2","author":"Pryadkina","year":"2015","journal-title":"Mol. Ther.-Meth Clin. D"},{"key":"ref_72","unstructured":"(2024, March 07). Clinicaltrials.gov. A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants with Limb Girdle Muscular Dystrophy, Type 2B\/R2 (LGMD2B\/R2, Dysferlin [DYSF] Related), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05906251#publications."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/s41591-021-01467-7","article-title":"Record number of gene-therapy trials, despite setbacks","volume":"27","author":"Arnold","year":"2021","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41587-020-00756-9","article-title":"Safety questions for AAV gene therapy","volume":"39","author":"Venditti","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101125","DOI":"10.1016\/j.omtm.2023.101125","article-title":"Clinical holds for cell and gene therapy trials: Risks, impact, and lessons learned","volume":"31","author":"Wills","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat. Methods"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Horodecka, K., and Duchler, M. (2021). CRISPR\/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116072"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/mt.2016.40","article-title":"Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy","volume":"24","author":"Turan","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mou, H., Smith, J.L., Peng, L., Yin, H., Moore, J., Zhang, X.O., Song, C.Q., Sheel, A., Wu, Q., and Ozata, D.M. (2017). CRISPR\/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol., 18.","DOI":"10.1186\/s13059-017-1237-8"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy","volume":"67","author":"Malik","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1111\/jcmm.15319","article-title":"Effect of Ataluren on dystrophin mutations","volume":"24","author":"Berger","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.stemcr.2022.08.005","article-title":"Investigation of PTC124-mediated translational readthrough in a retinal organoid model of AIPL1-associated Leber congenital amaurosis","volume":"17","author":"Leung","year":"2022","journal-title":"Stem Cell Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Boeck","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Samanta, A., Stingl, K., Kohl, S., Ries, J., Linnert, J., and Nagel-Wolfrum, K. (2019). Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246274"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41467-022-30080-6","article-title":"Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2021.04.015","article-title":"Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation","volume":"21","author":"Seo","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"103667","DOI":"10.1016\/j.isci.2021.103667","article-title":"4-Phenylbutyrate restores localization and membrane repair to human dysferlin mutations","volume":"25","author":"Tominaga","year":"2022","journal-title":"iScience"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","article-title":"Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping","volume":"39","author":"Li","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Flynn, L.L., Mitrpant, C., Adams, A., Pitout, I.L., Stirnweiss, A., Fletcher, S., and Wilton, S.D. (2021). Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050552"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fgene.2019.01249","article-title":"Consequences of Making the Inactive Active Through Changes in Antisense Oligonucleotide Chemistries","volume":"10","author":"Zaw","year":"2019","journal-title":"Front. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1261\/rna.079511.122","article-title":"Future directions for medicinal chemistry in the field of oligonucleotide therapeutics","volume":"29","author":"Hall","year":"2023","journal-title":"RNA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","article-title":"Casimersen for Duchenne muscular dystrophy","volume":"57","author":"Yokota","year":"2021","journal-title":"Drugs Today Barc"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides","volume":"27","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: First Global Approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1756285618754459","DOI":"10.1177\/1756285618754459","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/15353702221082612","article-title":"Mechanisms of disease-associated SINE-VNTR-Alus","volume":"247","author":"Pfaff","year":"2022","journal-title":"Exp. Biol. Med. Maywood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/JND-150109","article-title":"Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients\u2019 Cells","volume":"2","author":"Barthelemy","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acn3.96","article-title":"A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides","volume":"1","author":"Dominov","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acn3.738","article-title":"Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation","volume":"6","author":"Dominov","year":"2019","journal-title":"Ann. Clin. Transl. Neur"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/jhg.2010.49","article-title":"Mutation spectrum of the dystrophin gene in 442 Duchenne\/Becker muscular dystrophy cases from one Japanese referral center","volume":"55","author":"Takeshima","year":"2010","journal-title":"J. Hum. Genet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Anwar, S., Mir, F., and Yokota, T. (2023). Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041130"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Agrawal, S. (2021). The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050503"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1021\/acsomega.7b00291","article-title":"Chemical Modification of the siRNA Seed Region Suppresses Off-Target Effects by Steric Hindrance to Base-Pairing with Targets","volume":"2","author":"Iribe","year":"2017","journal-title":"ACS Omega"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7972","DOI":"10.1038\/s41467-023-43714-0","article-title":"Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry","volume":"14","author":"Terada","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.omtn.2023.02.007","article-title":"Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics","volume":"31","author":"Maksudov","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"16240","DOI":"10.1021\/jacs.0c04335","article-title":"Synthesis and Characterization of Thiophosphoramidate Morpholino Oligonucleotides and Chimeras","volume":"142","author":"Langner","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e2207956119","DOI":"10.1073\/pnas.2207956119","article-title":"Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing","volume":"119","author":"Le","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Paul, S., and Caruthers, M.H. (2023). Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry. Molecules, 28.","DOI":"10.3390\/molecules28145380"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Tran, P., Weldemichael, T., Liu, Z., and Li, H.Y. (2022). Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020342"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3762\/bjnano.11.10","article-title":"Internalization mechanisms of cell-penetrating peptides","volume":"11","author":"Ruseska","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Liu, B.R., Chiou, S.H., Huang, Y.W., and Lee, H.J. (2022). Bio-Membrane Internalization Mechanisms of Arginine-Rich Cell-Penetrating Peptides in Various Species. Membranes, 12.","DOI":"10.3390\/membranes12010088"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1089\/hum.2022.069","article-title":"Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1","volume":"33","author":"Jauvin","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/mt.2008.120","article-title":"Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-021-03184-z","article-title":"Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: An update","volume":"96","author":"Sheikh","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Kulkarni","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Calero, M., Moleiro, L.H., Sayd, A., Dorca, Y., Miquel-Rio, L., Paz, V., Robledo-Montana, J., Enciso, E., Accion, F., and Herraez-Aguilar, D. (2022). Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.887678"},{"key":"ref_129","first-page":"292","article-title":"Delivery of therapeutic oligonucleotides in nanoscale","volume":"7","author":"Wu","year":"2022","journal-title":"Bioact. Mater."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Coated Polymeric Nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s13311-018-0648-x","article-title":"The Limb-Girdle Muscular Dystrophies: Is Treatment on the Horizon?","volume":"15","author":"Chu","year":"2018","journal-title":"Neurotherapeutics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:45:29Z","timestamp":1760107529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":131,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25115572"],"URL":"https:\/\/doi.org\/10.3390\/ijms25115572","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}